Govert de With
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Govert de With has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
P. de Jong
Nuclear Research and Consultancy Group (NRG), Utrechtseweg 310, NL-6800 ES Arnhem, The Netherlands
3 shared publications- Anna Sarnelli
Medical Physics Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, 47014 Meldola, Italy
2 shared publications - Cipriana Stefanescu
Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iași, Romania
2 shared publications - Dimitris Visvikis
LaTIM UMR 1101, Inserm, Brest, France
2 shared publications - Fangli Qiao
First Institute of Oceanography and Key Laboratory of Marine Science and Numerical Modeling Ministry of Natural Resources Qingdao China
2 shared publications - Jane K. Sosabowski
Barts Cancer Institute—A Cancer Research UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK
2 shared publications
Latest Publications
- Open Access
- 18 October 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (10) , 1578
Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project
This review comprehensively assesses the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment. The approval of radium-223 therapy in 2013 marked a significant advancement in alpha-emitting therapeutic radiopharmaceuticals, which are primarily used in treatment of prostate cancer. The EU SECURE project was introduced as a major initiative to enhance the sustainability and safety of medical alpha-emitting radionuclides production in Europe. This literature review was conducted by a multidisciplinary team on selected radionuclides, including actinium-225, bismuth-213, astatine-211, lead-212, terbium-149, radium-223 and thorium-227. These were selected based on their clinical significance, as identified in the EU PRISMAP project and subsequent literature searches. The review process involved searching major databases using specific keywords related to alpha-emitter therapy and was limited to articles in English. For each selected radionuclide, the physical characteristics, the radiochemistry, and the pre-clinical and clinical studies are explored. Actinium-225 is the most widely studied alpha emitter, with several preclinical and clinical studies on prostate cancer and neuroendocrine tumours. Other types of tumours (such as glioblastoma) still require preclinical and clinical development. Bismuth-213 bound to antibodies, peptides and nanobodies has shown optimal results in preclinical and clinical studies, with increased median survival and no significant toxicity. Astatine-211 differs from most other α-emitters relevant to TAT, since it yields one α-particle per decay. This offers certain translational advantages, including the simplification of radiation dosimetry calculations and quality control (QC). Lead-212 has the advantage of being an in situ generator with likely widespread availability. Although clinical data are limited, the findings are promising at this stage. The unconventional production of Terbium-149 is the primary reason it has not yet progressed to clinical trials. Overcoming this production obstacle would allow more detailed preclinical investigations. Optimal results with Thorium-227-labelled agents have been observed in preclinical studies, including delays in cellular growth, multiple double-strand breaks and complete regression. Intermediate phase I trial results have also been reported, demonstrating safety and tolerability, as well as an objective response rate of 25%.: The results highlight the advantages of alpha particles in targeting cancer cells with minimal radiation to normal tissue, emphasising the need for high specificity and stability in delivery mechanisms, as well as suggesting that the full clinical potential of alpha particle therapy remains unexplored. Theranostic approach and dosimetric evaluations still represent relevant challenges.
- 18 October 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (10) , 1578
Open AccessRecommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project
This review comprehensively assesses the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment. The approval of radium-223 therapy in 2013 marked a significant advancement in alpha-emitting therapeutic radiopharmaceuticals, which are primarily used in treatment of prostate cancer. The EU SECURE project was introduced as a major initiative to enhance the sustainability and safety of medical alpha-emitting radionuclides production in Europe. This literature review was conducted by a multidisciplinary team on selected radionuclides, including actinium-225, bismuth-213, astatine-211, lead-212, terbium-149, radium-223 and thorium-227. These were selected based on their clinical significance, as identified in the EU PRISMAP project and subsequent literature searches. The review process involved searching major databases using specific keywords related to alpha-emitter therapy and was limited to articles in English. For each selected radionuclide, the physical characteristics, the radiochemistry, and the pre-clinical and clinical studies are explored. Actinium-225 is the most widely studied alpha emitter, with several preclinical and clinical studies on prostate cancer and neuroendocrine tumours. Other types of tumours (such as glioblastoma) still require preclinical and clinical development. Bismuth-213 bound to antibodies, peptides and nanobodies has shown optimal results in preclinical and clinical studies, with increased median survival and no significant toxicity. Astatine-211 differs from most other α-emitters relevant to TAT, since it yields one α-particle per decay. This offers certain translational advantages, including the simplification of radiation dosimetry calculations and quality control (QC). Lead-212 has the advantage of being an in situ generator with likely widespread availability. Although clinical data are limited, the findings are promising at this stage. The unconventional production of Terbium-149 is the primary reason it has not yet progressed to clinical trials. Overcoming this production obstacle would allow more detailed preclinical investigations. Optimal results with Thorium-227-labelled agents have been observed in preclinical studies, including delays in cellular growth, multiple double-strand breaks and complete regression. Intermediate phase I trial results have also been reported, demonstrating safety and tolerability, as well as an objective response rate of 25%.: The results highlight the advantages of alpha particles in targeting cancer cells with minimal radiation to normal tissue, emphasising the need for high specificity and stability in delivery mechanisms, as well as suggesting that the full clinical potential of alpha particle therapy remains unexplored. Theranostic approach and dosimetric evaluations still represent relevant challenges.
- Open Access
- 13 August 2025
- Published by MDPI AG in Preprints.org
Recommendations on the Clinical Application and Future Potential of α-Particle Therapy. A Comprehensive Review of the Results from the SECURE Project
Background/Objectives The document comprehensively reviews the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment. The approval of radium-223 (Ra-223) therapy in 2013 marked a significant advancement in alpha-emitting therapeutic radiopharmaceuticals, which are primarily used in treatment of prostate cancer. The EU SECURE project was introduced as a major initiative to enhance the sustainability and safety of medical alpha-emitting radionuclides production in Europe. Methods: This literature review was conducted by a multidisciplinary team on selected radionuclides, including actinium-225, bismuth-213, astatine-211, lead-212, terbium-149, radium-22323 and thorium-227. These were selected based on their clinical significance, as identified in the EU PRISMAP project and subsequent literature searches. The review process involved searching major databases using specific keywords related to alpha-emitter therapy and was limited to articles in English. For each selected radionuclide, the physical characteristics, the radiochemistry, and the pre-clinical and clinical studies are explored. Results of the review show current and potential clinical applications of new alpha-emitting radionuclides, sharing insights from the SECURE consortium’s experiences and providing recommendations for future clinical trials to establish the therapeutic efficacy of these radionuclides. Conclusion: For each selected radionuclide, conclusion are reported in individual chapters. The results highlight the advantages of alpha particles in targeting cancer cells with minimal radiation to normal tissue, emphasising the need for high specificity and stability in delivery mechanisms, but also suggest that the full clinical potential of alpha particle therapy remains unexplored. Theranostic approach and dosimetric evaluations still represent relevant challenges.
- 13 August 2025
- Published by MDPI AG in Preprints.org
Open AccessRecommendations on the Clinical Application and Future Potential of α-Particle Therapy. A Comprehensive Review of the Results from the SECURE Project
Background/Objectives The document comprehensively reviews the clinical applications and future potential of alpha-emitting radionuclides available for targeted alpha-particle therapy (TAT) in cancer treatment. The approval of radium-223 (Ra-223) therapy in 2013 marked a significant advancement in alpha-emitting therapeutic radiopharmaceuticals, which are primarily used in treatment of prostate cancer. The EU SECURE project was introduced as a major initiative to enhance the sustainability and safety of medical alpha-emitting radionuclides production in Europe. Methods: This literature review was conducted by a multidisciplinary team on selected radionuclides, including actinium-225, bismuth-213, astatine-211, lead-212, terbium-149, radium-22323 and thorium-227. These were selected based on their clinical significance, as identified in the EU PRISMAP project and subsequent literature searches. The review process involved searching major databases using specific keywords related to alpha-emitter therapy and was limited to articles in English. For each selected radionuclide, the physical characteristics, the radiochemistry, and the pre-clinical and clinical studies are explored. Results of the review show current and potential clinical applications of new alpha-emitting radionuclides, sharing insights from the SECURE consortium’s experiences and providing recommendations for future clinical trials to establish the therapeutic efficacy of these radionuclides. Conclusion: For each selected radionuclide, conclusion are reported in individual chapters. The results highlight the advantages of alpha particles in targeting cancer cells with minimal radiation to normal tissue, emphasising the need for high specificity and stability in delivery mechanisms, but also suggest that the full clinical potential of alpha particle therapy remains unexplored. Theranostic approach and dosimetric evaluations still represent relevant challenges.
- Open Access
- 20 February 2025
- Published by Oxford University Press (OUP) in Radiation Protection Dosimetry
- Vol. 201 (3) , 223-246
Results of the joint IAEA/EEAE Intercomparison exercise on radioanalytical characterization of NORM samples in the European region
Naturally Occurring Radioactive Material (NORM) may pose radiological risks across various industrial processes. Characterizing NORM is challenging due to radionuclide diversity, complex material matrices, and the multiple analytical techniques required. This study documents an Intercomparison Exercise (ICE) on the radioanalytical characterization of NORM, organized by International Atomic Energy Agency and EEAE to evaluate participants’ abilities to implement appropriate radioanalytical techniques and promote harmonization, thus contributing to ongoing optimization efforts into radiation protection of workers and the public. Thirty-one laboratories from 21 countries participated and determined the activity concentrations of long-lived radionuclides such as 40K, 238U, 226Ra, and 232Th in two ICE items, most through gamma spectrometry. Improper handling and insufficient testing of equilibria status within uranium and thorium series were key sources of unsatisfactory results. Notably, laboratories’ accreditation status did not correlate with analytical accuracy. Overall, study findings highlight improvements are needed in sample preparation, assumptions’ validation and measurement uncertainty budget estimation procedures.
- 20 February 2025
- Published by Oxford University Press (OUP) in Radiation Protection Dosimetry
- Vol. 201 (3) , 223-246
Open AccessResults of the joint IAEA/EEAE Intercomparison exercise on radioanalytical characterization of NORM samples in the European region
Naturally Occurring Radioactive Material (NORM) may pose radiological risks across various industrial processes. Characterizing NORM is challenging due to radionuclide diversity, complex material matrices, and the multiple analytical techniques required. This study documents an Intercomparison Exercise (ICE) on the radioanalytical characterization of NORM, organized by International Atomic Energy Agency and EEAE to evaluate participants’ abilities to implement appropriate radioanalytical techniques and promote harmonization, thus contributing to ongoing optimization efforts into radiation protection of workers and the public. Thirty-one laboratories from 21 countries participated and determined the activity concentrations of long-lived radionuclides such as 40K, 238U, 226Ra, and 232Th in two ICE items, most through gamma spectrometry. Improper handling and insufficient testing of equilibria status within uranium and thorium series were key sources of unsatisfactory results. Notably, laboratories’ accreditation status did not correlate with analytical accuracy. Overall, study findings highlight improvements are needed in sample preparation, assumptions’ validation and measurement uncertainty budget estimation procedures.
- 14 August 2023
- Published by Elsevier in Journal of Environmental Radioactivity
- Vol. 270, 107271
Comparison of methods for the radiological impact assessment of aquatic releases to the waters in the low countries
- 14 August 2023
- Published by Elsevier in Journal of Environmental Radioactivity
- Vol. 270, 107271
Comparison of methods for the radiological impact assessment of aquatic releases to the waters in the low countries
- 1 March 2021
- Published by Elsevier in Journal of Environmental Radioactivity
- Vol. 228, 106510
Intercomparison on the measurement of the thoron exhalation rate from building materials
- 1 March 2021
- Published by Elsevier in Journal of Environmental Radioactivity
- Vol. 228, 106510
Intercomparison on the measurement of the thoron exhalation rate from building materials
- 1 March 2018
- Published by Elsevier in Journal of Environmental Radioactivity
- Vol. 183, 73-81
Thoron exposure in Dutch dwellings – An overview
- 1 March 2018
- Published by Elsevier in Journal of Environmental Radioactivity
- Vol. 183, 73-81
Thoron exposure in Dutch dwellings – An overview
- 25 May 2017
- Published by ASME International in Journal of Nuclear Engineering and Radiation Science
- Vol. 3 (3) , 030904
Impact From Fly Ash as Additive to Concrete on the Radiation Exposure in Dwellings
Fly ash is widely used as a supplementary cementitious material in the production of cement and concrete, and improves durability and strength of the concrete. However, as for all materials of mineral origin, fly ash is a source for natural radioactivity; hence, its need for responsible use. The aim of this study is to investigate the radiation impact from fly ash as an additive to concrete compared against concrete without fly ash. For this purpose, eight concrete mixtures are experimentally tested, followed by a computation of the radiation dose when used as bulk material in building constructions. The results demonstrate an increase in the total radiation dose from around 0.8 mSv with no fly ash up to 0.92 mSv when fly ash is used. The increase mostly comes from external radiation, while the radon exhalation factor is reduced and sometimes even reduces the radon dose despite the higher radium content. The work has demonstrated that the impact from fly ash on the radiation exposure is limited when applied as a supplementary cementitious material. At the same time, fly ash provides real benefits to the quality and durability of the concrete. For this reason, exemption strategies for such applications should be developed.
- 25 May 2017
- Published by ASME International in Journal of Nuclear Engineering and Radiation Science
- Vol. 3 (3) , 030904
Impact From Fly Ash as Additive to Concrete on the Radiation Exposure in Dwellings
Fly ash is widely used as a supplementary cementitious material in the production of cement and concrete, and improves durability and strength of the concrete. However, as for all materials of mineral origin, fly ash is a source for natural radioactivity; hence, its need for responsible use. The aim of this study is to investigate the radiation impact from fly ash as an additive to concrete compared against concrete without fly ash. For this purpose, eight concrete mixtures are experimentally tested, followed by a computation of the radiation dose when used as bulk material in building constructions. The results demonstrate an increase in the total radiation dose from around 0.8 mSv with no fly ash up to 0.92 mSv when fly ash is used. The increase mostly comes from external radiation, while the radon exhalation factor is reduced and sometimes even reduces the radon dose despite the higher radium content. The work has demonstrated that the impact from fly ash on the radiation exposure is limited when applied as a supplementary cementitious material. At the same time, fly ash provides real benefits to the quality and durability of the concrete. For this reason, exemption strategies for such applications should be developed.
- 1 July 2016
- Published by Elsevier in Journal of Environmental Radioactivity
- Vol. 158-159, 56-63
Impact from indoor air mixing on the thoron progeny concentration and attachment fraction
- 1 July 2016
- Published by Elsevier in Journal of Environmental Radioactivity
- Vol. 158-159, 56-63
Impact from indoor air mixing on the thoron progeny concentration and attachment fraction
- 1 October 2014
- Published by Elsevier in Science of The Total Environment
- Vol. 494-495, 261-271
Dispersion and fate of 90Sr in the Northwestern Pacific and adjacent seas: Global fallout and the Fukushima Dai-ichi accident
- 1 October 2014
- Published by Elsevier in Science of The Total Environment
- Vol. 494-495, 261-271
Dispersion and fate of 90Sr in the Northwestern Pacific and adjacent seas: Global fallout and the Fukushima Dai-ichi accident